Business Context and Reporting Period
This Form 8-K, dated November 28, 2023, is filed by 180 Life Sciences Corp. (not Forum Markets Inc. as indicated in metadata). The report details a material definitive agreement entered into on November 28, 2023, to amend a prior securities purchase agreement and address non-compliance with Nasdaq Listing Rule 5635(d) regarding shareholder approval requirements.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to the specific transaction:
- Additional Cash Proceeds: The Purchaser agreed to pay an additional $830,769.30 (the "Repricing Amount").
- New Securities Issued:
- Pre-funded warrants to purchase up to 4,886,878 shares of Common Stock at $0.0001 per share.
- Common warrants to purchase up to 9,064,098 shares of Common Stock at $0.17 per share.
- Total Potential Dilution: The new warrants cover 13,950,976 shares of Common Stock.
Material Changes and Prior Period Comparison
This filing represents a modification of the August 9, 2023, Securities Purchase Agreement (SPA). The material changes include:
- Repricing: Adjustment of the August Shares and August Pre-Funded Warrants to secure the additional $830,769.30 payment.
- Warrant Restructuring: Existing Common Warrants (covering approximately 9.06 million shares) were amended to set the exercise price at $0.17 per share and to delay exercisability until shareholder approval is obtained.
- Compliance Status: The transaction is designed to restore compliance with Nasdaq Listing Rule 5635(d), which the company was notified it was violating on October 13, 2023.
Outlook, Risks, and Contingencies
Management Commentary and Conditions:
- Shareholder Approval Requirement: The new and amended warrants are not exercisable until the company obtains stockholder approval for the issuance of the underlying shares.
- Meeting Schedule: The company must hold a stockholder meeting within 90 days of the closing (expected December 1, 2023). If approval is not obtained, meetings will be held every 90 days thereafter until approval is granted or the warrants expire.
- Issuance Moratorium: The company agreed not to issue additional Common Stock or equivalents from the closing date until 15 days after the stockholder approval date.
- Registration Obligation: The company must file a registration statement with the SEC within 60 days of the amendment date to register the resale of the warrant shares.
Risks: Failure to obtain stockholder approval within the stipulated timelines could result in the warrants remaining unexercisable or expiring, potentially impacting the company's capital structure and investor relations.
Investor Verification Checklist
- Verify the exact closing date of the transaction (expected December 1, 2023) and confirmation of the $830,769.30 receipt.
- Monitor the filing of the registration statement with the SEC within the 60-day window post-amendment.
- Track the scheduling and outcome of the required stockholder meeting to be held within 90 days of closing.
- Confirm the company's status regarding Nasdaq Listing Rule 5635(d) compliance following the closing.
- Review the full text of the Warrant Amendment Agreement and SPA Amendment (Exhibits 4.4 and 10.1) for specific termination provisions and covenants.